Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.1
2.5
Journals
Epigenomes
Special Issues
Targeting the Epigenetic Machinery to Enhance Cancer Immunotherapy
share announcement

Targeting the Epigenetic Machinery to Enhance Cancer Immunotherapy

A special issue of Epigenomes (ISSN 2075-4655).

Deadline for manuscript submissions: closed (25 December 2020) | Viewed by 12714

Special Issue Editors

Prof. Dr. Michael Chan

E-Mail Website
Guest Editor
Department of Biomedical Sciences, National Chung Cheng University, Chia Yi, Taiwan
Interests: cancer; epigenetics; biomarkers; bioinformatics; signaling pathway
Dr. Peter J. K. Kuppen

E-Mail Website
Guest Editor
Department of Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
Interests: colorectal cancer; tumor-immmune interactions; cancer genetics and epigenetics; immunotherapy; biomarkers
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer immunotherapy, such as immune checkpoint blockade, is effective against human cancer. However, only a subset of patients benefit from this novel therapy. It is, therefore, important to explore the mechanism behind this phenomenon. Recent evidence suggest that cancer cells may alter the epigenetic machinery, that controls RNA expression, for instance by DNA methylation and histon modifications, to evade the immune attack. In this special issue, we invite researchers to submit original research articles or reviews to uncover how targeting the epigenetic machinery can enhance cancer immunotherapy in human cancer.

Dr. Peter Kuppen
Prof. Michael Chan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Epigenomes is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Review

3 pages, 473 KiB  
Editorial
Firing up Cold Tumors—Targeting the Epigenetic Machinery to Enhance Cancer Immunotherapy
by Guan-Ling Lin, Leah H. J. Tsai, Peter J. K. Kuppen and Michael W. Y. Chan
Epigenomes 2021, 5(2), 11; https://0-doi-org.brum.beds.ac.uk/10.3390/epigenomes5020011 - 03 May 2021
Cited by 1 | Viewed by 3532
Abstract
Cancer immunotherapy using monoclonal antibodies targeting immune checkpoint proteins, such as PD-L1 or PD-1 (i [...] Full article
(This article belongs to the Special Issue Targeting the Epigenetic Machinery to Enhance Cancer Immunotherapy)
►▼ Show Figures

Figure 1

Review

Jump to: Editorial

15 pages, 812 KiB  
Review
Combinatorial Epigenetic and Immunotherapy in Breast Cancer Management: A Literature Review
by Yu-Ting Lee, Yu-Ming Chuang and Michael W. Y. Chan
Epigenomes 2020, 4(4), 27; https://0-doi-org.brum.beds.ac.uk/10.3390/epigenomes4040027 - 04 Dec 2020
Cited by 7 | Viewed by 4020
Abstract
Breast cancer is one of the leading causes of death among cancer patients worldwide. To date, there are several drugs that have been developed for breast cancer therapy. In the 21st century, immunotherapy is considered a pioneering method for improving the management of [...] Read more.
Breast cancer is one of the leading causes of death among cancer patients worldwide. To date, there are several drugs that have been developed for breast cancer therapy. In the 21st century, immunotherapy is considered a pioneering method for improving the management of malignancies; however, breast cancer is an exception. According to the immunoediting model, many immunosuppressive cells contribute to immunological quiescence. Therefore, there is an urgent need to enhance the therapeutic efficacy of breast cancer treatments. In the last few years, numerous combinatorial therapies involving immune checkpoint blockade have been demonstrated that effectively improve clinical outcomes in breast cancer and combining these with methods of targeting epigenetic regulators is also an innovative strategy. Nevertheless, few studies have discussed the benefits of epi-drugs in non-cancerous cells. In this review, we give a brief overview of ongoing clinical trials involving combinatorial immunotherapy with epi-drugs in breast cancer and discuss the role of epi-drugs in the tumor microenvironment, including the results of recent research. Full article
(This article belongs to the Special Issue Targeting the Epigenetic Machinery to Enhance Cancer Immunotherapy)
►▼ Show Figures

Figure 1

17 pages, 1614 KiB  
Review
Epigenetic Regulation of the Non-Coding Genome: Opportunities for Immuno-Oncology
by Maria J. Barrero
Epigenomes 2020, 4(3), 22; https://0-doi-org.brum.beds.ac.uk/10.3390/epigenomes4030022 - 10 Sep 2020
Cited by 5 | Viewed by 4157
Abstract
The contribution of the non-coding genome to disease and its therapeutic potential have been largely unexplored. Recently, several epigenetic drugs developed for cancer treatment have been described to mediate therapeutic effects through the reactivation of the expression of transposable elements in cancer cells. [...] Read more.
The contribution of the non-coding genome to disease and its therapeutic potential have been largely unexplored. Recently, several epigenetic drugs developed for cancer treatment have been described to mediate therapeutic effects through the reactivation of the expression of transposable elements in cancer cells. This event activates innate immunity-related pathways and promotes the generation of neoantigens in tumor cells, improving the efficacy of immunotherapeutic treatments. This review focuses on the regulation of transposable elements by epigenetic inhibitors and its implications for immuno-oncology. Full article
(This article belongs to the Special Issue Targeting the Epigenetic Machinery to Enhance Cancer Immunotherapy)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop